- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
Patent holdings for IPC class A61K 47/65
Total number of patents in this class: 1389
10-year publication summary
|
22
|
50
|
64
|
123
|
210
|
209
|
199
|
195
|
200
|
81
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 18943 |
27 |
| SeaGen Inc | 554 |
23 |
| Bayer Pharma AG | 1096 |
20 |
| Daiichi Sankyo Company, Limited | 1829 |
19 |
| MedImmune Limited | 627 |
15 |
| Genentech, Inc. | 3742 |
14 |
| CytomX Therapeutics, Inc. | 205 |
13 |
| SynDevRx, Inc. | 43 |
13 |
| Bicyclerd Limited | 130 |
13 |
| Cornell University | 3036 |
12 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 588 |
12 |
| Bristol-myers Squibb Company | 5080 |
10 |
| Hoffmann-La Roche Inc. | 3060 |
10 |
| The Johns Hopkins University | 5377 |
10 |
| Duke University | 2872 |
10 |
| Case Western Reserve University | 1727 |
10 |
| ImmunoGen, Inc. | 405 |
10 |
| Immunwork Inc. | 21 |
10 |
| Genequantum Healthcare (Suzhou) Co., Ltd. | 42 |
10 |
| Bayer AG | 3045 |
9 |
| Other owners | 1119 |